OLX104C
- Phase 1 injection · RNA interference · OliX Pharmaceuticals · trial NCT07327359 · developer page · sponsor targets end 2026 for phase 2a first patient dosed (said Aug 2026)
RNA-interference therapy that silences the androgen receptor in scalp skin; phase 1a done, phase 1b/2a running in Australia
Information, not medical advice. Talk to a licensed doctor or pharmacist before starting or changing a treatment.
Research
— no indexed studies mention OLX104C in a hair context yet
All on OpenAlex →